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Abstract 
Fibroblasts degrade about 15% of newly synthesised collagen within the cell before it can be secreted. When the helical structure of 
collagen is disrupted, about 30% is degraded intracellularly. To determine if collagen degradation occurs in a pre-lysosomal compartment, 
the passage of type I collagen out of the endoplasmic reticulum or Golgi was inhibited by incubating human lung fibroblasts with 
brefeldin A or monensin. In both cases, the type I collagen retained within the cell was stable over a 20 h period. Disrupting the helical 
structure of collagen with cis-hydroxyproline, 2,2'-bipyridyl or ethyl 3,4-dihydroxybenzoate did not alter the stability of type I collagen in 
brefeldin or monensin-treated cells. Incubating permeabilised cells in the presence of GTI~S (guanosine 5'-(3-O-thio)triphosphate), which 
blocks transport out of the endoplasmic reticulum, also resulted in the stable retention of type I collagen. Addition of dithiothreitol to 
permeabilised cells failed to initiate intracellular degradation. Similar results were obtained with fibronectin. Both normal fibronectin and 
fibronectin in which canavanine r placed arginine were stable for 20 h in cells treated with brefeldin A or monensin. The degradation of 
native collagen is sensitive to inhibition by a cell-permeable cysteine proteinase inhibitor (ALLN) but is insensitive to chloroquine (which 
raises the pH of acidic intracellular compartments), whereas the degradation of abnormal collagen was sensitive to both ALLN and 
chloroquine. These results argue against he intracellular degradation of collagen or fibronectin in a pre-lysosomal compartment. 
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1. Introduction 
A major characteristic of fibrotic diseases is the exces- 
sive deposition of connective tissue, of which type I 
collagen and fibronectin are major components [1]. The 
rate of accumulation of collagen depends, of course, on the 
relative rates of synthesis and degradation. There appears 
to be general agreement that, in animal models of pul- 
monary fibrosis, there is increased collagen synthesis [2,3] 
but disagreement as to whether there is increased or de- 
creased degradation [3,4]. Using in vivo model systems of 
pulmonary fibrosis, pharmacological agents that inhibit 
collagen production and/or  enhance its degradation have 
Abbreviations: ALLN, acetyl-leucyl-leucyl-norleucinal; Endo H, 
endo-/3-N-acetylglucosaminidase H; GTPTS, guanosine 5'-(3-O-thio)tri- 
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been demonstrated to reduce the collagen deposition and 
functional abnormalities associated with this disease [2,3]. 
There are three major mechanisms of collagen degrada- 
tion. Firstly, collagen degradation may occur extracellu- 
larly through the action of specific collagenases. Secondly, 
collagen fibres may be endocytosed and degraded within 
lysosomes. Thirdly, a proportion of newly synthesised 
collagen is degraded intracellularly prior to secretion [5]. 
The turnover of cross-linked extracellular collagen is a 
relatively slow process [6]. However, in vitro experiments 
have demonstrated that the extent of intracellular degrada- 
tion of newly synthesised collagen varies from 15 to 30% 
[5,7,8]. Degradation of newly synthesised collagen has also 
been observed in several tissues in vivo and appears to 
increase dramatically with age [9]. Thus, the intracellular 
degradation of newly synthesised collagen prior to its 
secretion is a physiologically important mechanism for 
regulating collagen production. 
Both the function and mechanism of intracellular colla- 
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gen degradation are poorly understood. It may represent a 
mechanism of quality control for degrading incorrectly 
folded molecules. Indeed, collagen synthesised in the pres- 
ence of proline analogues or inhibitors of prolyl hydroxyl- 
ase does not fold correctly and is subjected to enhanced 
intracellular degradation [10,11]. Evidence has been pre- 
sented for and against he involvement of lysosomes in the 
degradation of malfolded collagens [8,12,13]. Evidence 
from studies using inhibitors of lysosomal function sug- 
gests that the degradation of normal collagen does not take 
place in lysosomes [8,11]. Little is known about he extent 
of intracellular degradation of other extracellular matrix 
components. Certain splicing variants of fibronectin are 
not secreted and are retained intracellularly where they 
were presumed to undergo degradation [14]. Several mem- 
brane and secretory proteins have been shown to be de- 
graded within the endoplasmic reticulum, especially when 
abnormally folded or synthesised in excess of other sub- 
units of a multi-subunit complex [15,16]. Abnormally 
folded collagens accumulate in the endoplasmic reticulum 
[17,18] which also contains a collagen-binding protein 
[19]. Several reagents are now available which inhibit the 
transport of secretory reagents at either the level of the 
endoplasmic reticulum (brefeldin A [20] or GTPT S [21]) or 
the Golgi (monensin [22]). We have now investigated the 
intracellular stability of type I collagen and fibronectin in 
human lung fibroblasts in which protein secretion is 
blocked at various stages of the secretory pathway. 
2. Materials and methods 
2.1. Tissue culture 
Human fetal lung fibroblasts (HFL-1) were obtained 
from The European Collection of Animal Cell Cultures 
(Porton, UK) at passage 14 and were used between pas- 
sage number 17-20. Cells were cultured in Dulbecco's 
modified Eagle's medium containing 5% fetal calf serum 
and ascorbic acid (100 /xg/ml). 
2.2. Metabolic labelling 
To determine the effects of brefeldin A and monensin 
(both purchased from Sigma, UK) on protein secretion, 
cells were labelled for 5 h with [35S]methionine 
(Amersham, UK), (50 /xCi/ml) in methionine-free 
medium. Monensin and brefeldin A were added 1 h before 
labelling. The culture medium was dialysed against water, 
freeze-dried and redissolved in PBS (phosphate-buffered 
saline). Aliquots were immunoprecipitated with rabbit anti- 
bodies to human type I procollagen or bovine fibronectin 
as described previously [23]. Immune complexes were 
collected on protein A-Sepharose, washed with PBS, dis- 
solved in SDS-PAGE sample buffer and analysed on 7.5% 
SDS-polyacrylamide g ls followed by fluorography. For 
quantitation, autoradiograms were scanned into a Macin- 
tosh computer using a Microtek 600ZS scanner and anal- 
ysed using the programme ScanAnalysis (BioSoft, Cam- 
bridge, UK). 
2.3. Pulse-chase xperiments 
Cells were labelled with [35S]methionine (100/zCi/ml) 
in methionine-free medium for 1 h, washed with PBS 
(× 3) and then chased in medium containing 4 mM me- 
thionine. Monensin (1 /zM) was added 1 h before labelling 
and was included in the pulse and chase medium. Brefeldin 
A was added with the pulse medium and was also included 
in the chase medium. At various times, cells were washed 
with PBS (× 3) and dissolved in 1% Triton X-100/0.05% 
SDS containing 1 mM PMSF, leupeptin (5 /zg/ml) and 
pepstatin (5 /xg/ml). Samples were immunoprecipitated 
with antibodies to type I collagen and fibronectin as 
described above. In some experiments, cells were cultured 
in the presence of cis-hydroxyproline (2.5 mM), 2,2'-bi- 
pyridyl (0.1 mM) or ethyl 3,4-dihydroxybenzoate (0.4 
raM). 
2.4. Assessment of collagen folding 
Type I collagen was isolated from the cell layer of 
HFL-1 cells pulse labelled with [35S]methionine for 1 h by 
immunoprecipitation as described above. After adsorption 
onto protein A-Sepharose, the beads were suspended in 10 
mM Tris-HC1 (pH 7.4) and incubated with chymotrypsin 
(100 /zg/ml) at 20°C for various times. The reaction was 
terminated by adding 4 × SDS-PAGE sample buffer and 
boiling for 2 min. Samples were analysed by electrophore- 
sis and chymotrypsin-resistant -chains were detected by 
fluorography and quantified by scanning densitometry. 
2.5. Determination of collagen stability in permeabilised 
cells 
After pulse labelling, cells were permeabilised with 
streptolysin O as described by Stafford and Bonifacino 
[24]. Permeabilised cells were chased in medium contain- 
ing 4 mM methionine, cytosol (0.5 mg protein/ml) pre- 
pared from rat liver [25] and an ATP-regenerating system 
(creatine phosphokinase, 0.2 units/ml, and 5 mM creatine 
phosphate). 
2.6. Determination of the rate of intracellular collagen 
degradation 
Cells were cultured in routine medium additionally 
supplemented with 0.2 mM proline and [U-14C]proline (10 
/zCi/ml) for 8 h. The [U-14C]proline was purified by 
chromatography on Dowex 50W-X8 immediately before 
use. The measurement of free and protein-bound [14C]hy- 
droxyproline was carried out as described previously [26]. 
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Fig. 1. Effect of brefeldin A and monensin on protein secretion. HFL-1 
cells were labelled with [35S]methionine (50 /xCi/rnl) for 5 h in the 
presence of various concentrations of brefeldin A (A) and monensin (B). 
Type I collagen ([]) and fibronectin (<)) were isolated from the culture 
medium by immunoprecipitation, subjected to SDS-PAGE and fluorogra- 
phy and relative amounts ecreted etermined by scanning densitometry. 
Results are the average of duplicate determinations. 
Intracellular collagen degradation is expressed as the ratio 
of free to total hydroxyproline X 100. 
2.7. Digestion of intracellular fibronectin with endo H 
Fibronectin was immunoprecipitated from extracts of 
cells incubated with brefeldin A or monensin and 
[35S]methionine for 1 h as described above. The protein 
A-Sepharose beads were suspended in 100 mM sodium 
phosphate (pH 6.1)/0.025% SDS/20 mM EDTA (50 /zl) 
and digested with endo H (5 mU) at 37°C for 14 h. As a 
control, cell extracts prepared form brefeldin A or mon- 
ensin treated cells were subjected to immunoprecipitation 
without endo H digestion. After washing, the beads were 
eluted with SDS-PAGE sample buffer and analysed by 
SDS-PAGE and fluorography. 
2.8. Effect of canavanine on total protein degradation 
Cells were labelled with [3H]leucine (2.5 /zCi/ml) for 
10 h in leucine- and arginine-free medium containing 
canavanine (0.5 mM). After incubation in routine medium 
containing 4 mM leucine for 16 h, the rate of intracellular 
protein degradation was measured as described previously 
[271. 
3. Results 
3.1. Effect of brefeldin A and monensin on the intracellular 
stability of type I collagen 
The concentration f brefeldin A and monensin required 
to inhibit the secretion of type I collagen and fibronectin in 
HFL-1 cells were demonstrated to be 2.5 /zg/ml and 1 
/zM respectively (Fig. 1). In the case of monensin, 10-15% 
of type I collagen was found in the medium after a 20 h 
incubation probably as the result of toxic effects of the 
ionophore. In control cells, pulsed with [35S]methionine 
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Fig. 2. Effect of brefeldin A and monensin on the intracellular stability of 
type I collagen. HFL-1 cells were pulse-labelled for 1 h with 
[358]methionine (100 ~,Ci/ml) and then chased in medium containing 4
mM methionine. Type I collagen was isolated from a cell extract by 
immunoprecipitation and SDS/PAGE and quantified by scanning den- 
sitometry after fluorography. (a) control cells, (b) cells cultured in the 
presence of brefeldin A (2.5 /xg/ml) or (c) cells cultured in the presence 
of monensin (1 p,M). Panel A shows the relative intensity of the oil 
chain of type I collagen of cells cultured in the presence of brefeldin A 
(O), monensin (C)) or control cells ([]). Panel B shows cells additionally 
cultured in the presence of cis-hydroxyproline (2.5 mM). Results are the 
average of duplicate determinations. 
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Fig. 3. Sensitivity of type I collagen to proteinase digestion. Type I 
collagen was isolated from the cell layer of HFL-1 cells pulse-labelled 
with [35S]methionine for 1 h by immunoprecipitation. Immune complexes 
were collected on protein A-Sepharose and the beads were incubated with 
chymotrypsin (100 /zg/ml of 10 mM Tris-HCl, pH 7.4). At various 
times, the reaction was stopped by boiling in SDS-PAGE-sample buffer. 
The reaction products were analysed by SDS-PAGE and fluorography 
and the relative intensity of o~ 1 chains determined by scanning densitom- 
etry. Control cells (I-7), cells treated with cis-hydroxyproline (C)), 2,2'- 
bipyridyl (~)  or ethyl 3,4-dihydroxybenzoate (a ) .  Results are the aver- 
age of duplicate determinations. 
and subsequently chased with unlabelled medium, type I 
collagen was rapidly secreted and the intracellular protein 
had a half-life of about 2 h. When secretion was blocked 
with brefeldin A or monensin, intracellular type I collagen 
was stable over a period of 20 h (Fig. 2A). Each kinetic 
experiment was carried out three times and the results 
varied by less than 15%. The small decrease in monensin- 
treated cells could be entirely accounted for by leakage of 
type I collagen into the culture medium. 
3.2. Effect of agents which disrupt the helical structure of 
collagen on its intracellular stability 
In cells cultured in the presence of cis-hydroxyproline, 
the secretion of type I collagen was retarded. Pulse-labelled 
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Fig. 4. Determination of the rate of intracellular collagen degradation 
HFL-I cells. Cells were labelled with [U-InC]proline (10 /xCi/ml) for 8 
h. Free and protein-bound [Inc]hydroxyproline were determined as de- 
scribed in Section 2. Intracellular collagen degradation is expressed as the 
ratio of free to total hydroxyproline× 100. The effects of brefeldin A 
(BFA) and monensin (MON) on intracellular collagen degradation were 
determined in control cultures and in cells treated with cis-hydroxy- 
proline (cisHyp). Results are the mean + S.D. of three determinations. 
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Fig. 5. Effects of inhibitors on intracellular collagen degradation. HFL-1 
cells were labelled with [U-~4C]proline for 8 h. Control cells or cells 
labelled in the presence of cis-hydroxyproline (cisHyp) were additionally 
treated with 1 /zM chloroquine (CQ) or 100 /zM acetyl-leucyl-leucyl- 
norleucinal (ALLN). Intracellular collagen degradation is expressed as the 
ratio of free to total hydroxyproline >< 100. Results are the mean +_ S.D. of 
three determinations. 
type I collagen had an intracellular half-life of about 4 h. 
When the cells were treated with brefeldin A or monensin, 
type I collagen synthesised in the presence of cis-hydroxy- 
proline was stable over 20 h (Fig. 2B). Similar results were 
obtained with type I collagens ynthesised in the presence 
of 2,2'-bipyridyl or ethyl 3,4-dihydroxybenzoate which are 
inhibitors of prolyl hydroxylase [28,29] (results not shown). 
The disruption of the helical structure of type I collagen 
synthesised in the presence of these three compounds was 
demonstrated by its increased sensitivity to proteinase 
digestion (Fig. 3). These results were confirmed by deter- 
mining the actual rate of intracellular collagen degradation 
by measuring the formation of free hydroxyproline (Fig. 
4). During the 8 h labelling period, 15% of the newly 
synthesised collagen was degraded intracellularly. When 
cis-hydroxyproline was included in the labelling medium, 
intracellular collagen degradation increased to 31%. 
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Fig. 6. Intracellular collagen stability in permeabilised cells. HFL-1 ceils 
were pulse-labelled for 1 h with [35S]methionine (100 /zCi/ml), perme- 
abilised with streptolysin O and then chased in medium containing 4 mM 
methionine. Type I collagen was isolated from a cell extract by immuno- 
precipitation and SDS-PAGE and quantified by scanning densitometry 
and fluorography. Control cells (v1), cells incubated with brefeldin A 
(O), brefeldin A+I  mM dithiothreitol (O)  or 100 /zM GTPTS (z,). 
Results are the average of duplicate determinations. 
L.M.B. Andersson, M.J. Warburton / Biochimica et Biophysica Acta 1268 (1995) 27-30 31 
a 
b 
0 2 4 6 8 IOh 
0.5- 
0 
1-t 
> 0.5- 
0 
0 5 10 15 20 
Time (h) 
Fig. 7. Effect of brefeldin A and raonensin on the intracellular stability of 
fibronectin. HFL-1 cells were pulse-labelled for1 h with [35S] methionine 
(100/xCi/ml) and then chased in medium containing 4 mM methionine. 
Fibronectin was isolated from a cell extract by immunoprecipitation and 
SDS-PAGE and quantified by scanning densitometry after fluorography. 
(a) Control cells, (b) cells cultured in the presence of brefeldin A (2.5 
/xg/ml) or (c) cells cultured in the presence of monensin (1 /xM). Panel 
A shows the relative intensity of fibronectin in cells cultured in the 
presence ofbrefeldin A (~), monensin (O) or control cells ([]). Panel B 
shows cells additionally cultured in the presence of canavanine (0.5 raM). 
Results are the average of duplicate determinations. 
subsequently cultured in the presence of cytosol and an 
ATP-generating system although the half-life of pulse- 
labelled type I collagen was increased to about 4 h (Fig. 
6). When cells were chased in the presence of brefeldin A, 
pulse-labelled type I collagen was stable for at least 10 h. 
Inclusion of dithiothreitol (1 mM) in brefeldin A-treated 
cultures failed to alter the stability of type I collagen or 
fibronectin. Addition of GTPyS (100 /zM) also resulted in 
the relatively stable intracellular retention of type I colla- 
gen. 
3.4. Effect of brefeldin A and monensin on the intracellular 
stability of fibronectin 
Pulse-labelled fibronectin was secreted from HFL-1 
cells with a half-life of about 1.5 h. Inclusion of brefeldin 
A or monensin in the culture medium inhibited fibronectin 
secretion and resulted in the stable intracellular accumula- 
tion of fibronectin (Fig. 7A). Fibronectin synthesised in 
brefeldin A-treated cells, but not monensin-treated cells, 
was partially sensitive to digestion with endogly- 
cosaminidase H, demonstrating that fibronectin is accessi- 
ble to Golgi-associated enzymes in monensin- but not 
brefeldin A-treated cultures (Fig. 8). We attempted to 
disrupt he structure of fibronectin by culturing the cells in 
the presence of canavanine, an analogue of arginine. The 
intracellular half-life of fibronectin synthesised in the pres- 
ence of canavanine was increased to about 3 h. Incubation 
with brefeldin A or monensin resulted in the stable reten- 
tion of canavanine-containing fibronectin within the cells 
(Fig. 7B). We did not directly measure the influence of 
canavanine incorporation on the susceptibility of fi- 
bronectin to proteinase digestion. However, the overall rate 
of cellular protein degradation i creased 3-fold in canava- 
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Brefeldin A and monensin substantially inhibited intra- 
cellular collagen degradation in both control and cis-hy- 
droxyproline-treated cells. The membrane permeable cys- 
teine proteinase inhibitor acetyl-leucyl-leucyl-norleucinal 
(ALLN) inhibited both the enhanced and basal rate of 
intracellular collagen degradation (Fig. 5), whereas other 
proteinase inhibitors, PMSF, leupeptin and pepstatin, had 
little effect (data not shown). Chloroquine only inhibited 
the enhanced rate observed in the presence of cis-hydroxy- 
proline (Fig. 5). 
3.3. Collagen stability in permeabilised cells 
Collagen secretion occutTed in cells that had been treated 
with streptolysin O to permeabilise the cell membrane and 
C D 
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Fig. 8. Endoglycosaminidase H sensitivity of pulse-labelled fibronectin. 
Fibronectin was immunoprecipitated from extracts of cells incubated with 
brefeldin A (A, C) or monensin (B, D) which had been pulse-labelled for 
1 h with [35S]methionine (100 /xCi/ml). Immune complexes were col- 
lected on protein A-Sepharose, the beads were suspended in 100 rnM 
sodium phosphate (pH 6.1)/0.025% SDS/20 mM EDTA and digested 
with (A, B) or without (C, D) endo H (5 mU) for 14 h at 37 ° C. The 
beads were then eluted with SDS-PAGE-sample buffer and analysed by 
SDS-PAGE and fluorography. 
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Fig. 9. Effect of canavanine on total protein degradation. HFL-1 cells 
were labelled with [3H]leucine (2.5 /zCi/ml) for 10 h in leucine- and 
arginine-free medium containing canavanine (0.5 raM) and then chased 
for 16 h in medium containing 4 mM leucine. Protein degradation is 
expressed as the ratio of free [3H]leucine released into the culture 
medium to total [3H]leucine X 100. Results are the mean + S.D. of three 
determinations. 
nine-treated cultures (Fig. 9). The cysteine proteinase in- 
hibitor ALLN was again effective at inhibiting total pro- 
tein degradation in control and analogue-treated cells, 
whereas chloroquine was ineffective in inhibiting the 
degradation of normal and abnormal proteins. 
4. Discussion 
Three reagents were used to block the secretion of type 
I collagen and fibronectin at defined points of the secretory 
pathway. Brefeldin A inhibits transport from the endoplas- 
mic reticulum to the cis-Golgi cisternae [20]. The retro- 
grade pathway from the Golgi to the endoplasmic reticu- 
lum is not affected by brefeldin A, with the result that the 
Golgi is effectively redistributed into the endoplasmic 
reticulum. Brefeldin A does not cause the trans-Golgi 
cisternae to redistribute into the endoplasmic reticulum. 
Non-hydrolysable analogues of GTP, e.g., GTPyS, also 
block transport of proteins from the endoplasmic reticulum 
to the cis-Golgi [21]. The role of small GTP-binding 
proteins in protein transport between organelles has re- 
cently been documented [30]. The Na ÷ ionophore mon- 
ensin blocks protein transport during passage out of the 
trans-Golgi [22]. The use of these reagents produces reten- 
tion of secretory proteins in either the endoplasmic reticu- 
lum or the Golgi and allows the degradative capabilities of 
these organelles to be investigated. 
Our results show that neither type I collagen nor fi- 
bronectin are degraded within the endoplasmic reticulum 
or Golgi. Both proteins are stable for at least 10-20 h in 
cells treated with brefeldin A, GTP),S or monensin. Treat- 
ment with brefeldin A has previously been shown to 
inhibit the breakdown of newly synthesised total collagen 
in human lung fibroblasts by measuring the production of 
free hydroxyproline [31]. The rate of degradation of newly 
synthesised collagen in HFL-1 cells was determined to be 
about 15%, which is within the range found by others 
[8,11,12]. The rate of collagen degradation does not vary 
significantly over the passage range 10-20 in HFL-1 cells 
[11]. If degradation of collagen occurred within the endo- 
plasmic reticulum or Golgi, then, over a 20 h chase period, 
the label incorporated into pulse-labelled newly synthe- 
sised type I collagen should decrease to about 20% of its 
original evel when secretion is blocked. This is clearly not 
the case. Cells treated with brefeldin A are still capable of 
degrading several membrane and secretory proteins, e.g., 
T-cell antigen receptor chains [15] and apolipoprotein B 
[32], demonstrating that the proteolytic activity associated 
with the degradation of these proteins is not inhibited by 
the disruption of organelle structure caused by brefeldin A. 
The effects of brefeldin A are not restricted to the Golgi; 
for example, the endosomal system and lysosomes adopt 
increased tubular characteristics although lysosomal degra- 
dation appears to be largely unaffected [20]. 
Monensin, which blocks transport out of the Golgi [22], 
also inhibited the intracellular degradation of collagen 
measured by the stability of pulse-labelled intracellular 
collagen and the formation of free hydroxyproline. Mon- 
ensin has previously been shown to increase the extent of 
intracellular collagen degradation in chick tendon cells 
[33]. However, for HFL-1 cells, we had to use a 10-fold 
higher concentration of monensin to completely inhibit 
secretion. The effects of monensin may also vary with cell 
type. For example, in most cells the delivery of lysosomal 
enzymes to lysosomes is inhibited by monensin [22] 
whereas in the plasma cell line MOPC 315 monensin has 
no effect on the transport of lysosomal enzymes [34]. In 
HFL-1 cells, monensin also inhibits the degradation of 
abnormally folded collagens, which has been reported to 
occur in lysosomes [12], suggesting that monensin blocks 
transport to the lysosomes in this cell line. These results 
suggest that intracellular collagen degradation occurs distal 
to the trans-Golgi. 
Permeabilised cell systems have proved useful for in- 
vestigating the effects on protein degradation of reagents 
which are normally unable to penetrate the cell surface 
membrane [24]. Permeabilised HFL-1 cells cultured in the 
presence of an ATP-regenerating system and cytosol se- 
crete type I collagen but at a slower rate than normal. 
Brefeldin A blocks secretion in permeabilised cells and the 
type I collagen that accumulates in these cells is stable for 
at least 10 h. The degradation of several proteins in 
permeabilised cells, e.g., the T-cell receptor a-chain [35], 
within the endoplasmic reticulum requires the presence of 
free sulfydryl groups. This was not the case for type I 
collagen or fibronectin which remained stable in brefeldin 
A-treated cells cultured in the presence of dithiothreitol. 
The transport of vesicles between the various compart- 
ments of the secretory pathway requires GTP-binding pro- 
teins of the rab gene family [30]. GTP3,S, a non-hydro- 
lysable analogue of GTP, is able to block transport be- 
tween the endoplasmic reticulum and the Golgi when 
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introduced into permeabilised cells [24]. GTPyS substan- 
tially inhibited the secretion of type I collagen and fi- 
bronectin in permeabilised HFL-1 cells, and the proteins 
retained intracellularly are largely stable. This result again 
indicates that degradation of these proteins does not take 
place in the endoplasmic reticulum. The decrease in the 
radioactivity associated with both proteins during the first 
hour of the chase can be accounted for by secretion of 
proteins which had already passed through the Golgi at the 
time of permeabilisation a d treatment with GTPyS. 
The use of reagents that inhibit lysosomal function, e.g., 
weak bases that raise lysosomal pH (e.g., chloroquine) and 
cysteine proteinase inhibitors (e.g., leupeptin), suggests 
that the degradation of abnormally folded collagen occurs 
within lysosomes [8,12]. In HFL-I cells treated with 
brefeldin A or monensin, abnormally folded collagens 
synthesised in the presence of cis-hydroxyproline, 2,2'-bi- 
pyridyl or ethyl 3,4-dihydroxybenzoate w re stable, 
demonstrating that the degradation of abnormally folded 
collagens does not occur in the endoplasmic reticulum or 
Golgi. The abnormal fohting of collagens produced by 
HFL-1 cells was demonstrated by their sensitivity to 
chymotrypsin. By measming the production of free hy- 
droxyproline, we were able to confirm that only the degra- 
dation of abnormally folded collagen could be inhibited by 
chloroquine. However, bolh the degradation of normal and 
malfolded collagens could be inhibited by the cysteine 
proteinase inhibitor ALLN. Cell membranes are imperme- 
able to leupeptin which can only gain limited access to 
lysosomes through pinocytosis [36] unlike ALLN, which 
can diffuse through cell membranes. ALLN also inhibits 
the degradation of certain proteins within the endoplasmic 
reticulum, e.g., secretory lgM in lymphocytes [37]. 
In conclusion, the intracellular degradation of newly 
synthesised type I collagen and fibronectin in HFL-1 cells 
does not take place in the endoplasmic reticulum or Golgi 
and must therefore occur between the trans-Golgi and 
lysosomes. Other secretoJaj proteins which are degraded 
within the lysosomal compartment i clude amyloid precur- 
sor protein [38] and apolipoprotein E [39]. It therefore 
remains possible that the degradation of both normal and 
malfolded collagens and fibronectin occurs in the endoso- 
mal/lysosomal compartment through a pH-insensitive 
mechanism, possibly analogous to the co-operation ob- 
served between eutral collagenase and acidic cathepsins 
that is reported to occur during bone resorption [40]. 
Although cathepsins B and L can degrade denatured colla- 
gens and the telopeptides of native collagens, they are 
unable to degrade triple-helical regions even at acid pH 
[41]. The ability of lysosomes to degrade native collagens 
has been demonstrated by their ability to break down 
endocytosed collagen fibrils [42], although the mechanism 
remains unclear. Many cells, especially in culture, secrete 
lysosomal enzymes [43], and the proteolytic processing of 
secretory proteins within secretory vesicles has been ob- 
served [44]. The possibility that collagens and proteinases 
are secreted in the same vesicles remains to be investi- 
gated. 
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